Literature DB >> 25339146

Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients.

Li-chen Gao1, Di Wang, Fang-qun Liu, Zheng-yu Huang, Hong-guang Huang, Gui-hua Wang, Xi Chen, Qun-zhi Shi, Li Hong, Li-ping Wu, Jie Tang.   

Abstract

PURPOSE: The purpose of this study is to evaluate the association between variants in prostaglandin-endoperoxide synthase 1 (PTGS1), prostaglandin F (2α) receptor (PTGFR), and multidrug resistance protein 4 (MRP4) genes and intraocular pressure (IOP) response to latanoprost in Chinese patients with primary open-angle glaucoma (POAG).
METHODS: The IOP response to latanoprost was evaluated by percent IOP reduction (%ΔIOP) in the treated eye with the formula %ΔIOP = (Baseline IOP values - IOP values posttreatment) / Baseline IOP values × 100 %. Polymorphisms in PTGS1 (rs3842787 and rs10306114), PTGFR (rs3753380 and rs3766355), and MRP4 (rs11568658 and rs11568668) genes were detected by direct DNA sequencing. The differences among %ΔIOP of genotypes or haplotypes were obtained by use of the Mann-Whitney U test. Association analyses were performed by multiple linear regression analysis.
RESULTS: Latanoprost were prescribed to 63 subjects, 60 of which met the inclusion/exclusion criteria for the current study. Notably, the %ΔIOP in the rs11568658 GT heterozygous genotype was 10.4 %ΔIOP lower than that of GG homozygous wild-type on day 7 (15.7 ± 2.52 vs. 26.1 ± 2.88, P=0.003), and the corresponding results in the rs10306114 AG heterozygous genotype and AT haplotype constructed by rs3753380 and rs3766355 on day 7 were 7.2 and 10.3 %ΔIOP (P<0.05). Interestingly, similar results were also observed on day 30 (P=0.008, P=0.006, and P=0.002, respectively). Multiple regression analysis showed that heterozygous genotypes of rs10306114, rs11568658, and carrier of AT haplotype were significantly correlated with the lower %ΔIOP. On day 30, the above variations explained 9.9, 10.7, and 17.7 % of the total variability of %ΔIOP in the Chinese POAG patients, respectively.
CONCLUSION: rs10306114, rs3753380, rs3766355, and rs11568658 single-nucleotide polymorphisms (SNPs) correlate with a response to latanoprost treatment in patients with POAG. These SNPs may be important determinants of variability in response to latanoprost.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339146     DOI: 10.1007/s00228-014-1769-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.

Authors:  Ichiro Kawaguchi; Tomomi Higashide; Shinji Ohkubo; Chiaki Kawaguchi; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-06-07       Impact factor: 2.447

2.  Lack of association between polymorphisms in the prostaglandin F2α receptor and solute carrier organic anion transporter family 2A1 genes and intraocular pressure response to prostaglandin analogs.

Authors:  Catherine A McCarty; Richard Berg; Richard Patchett; Russell A Wilke; James K Burmester
Journal:  Ophthalmic Genet       Date:  2011-11-07       Impact factor: 1.803

3.  Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.

Authors:  Y Tamada; T Taniguchi; H Murase; T Yamamoto; Y Kitazawa
Journal:  J Ocul Pharmacol Ther       Date:  2001-02       Impact factor: 2.671

4.  Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations.

Authors:  Cornelia M Ulrich; Jeannette Bigler; Justin Sibert; Elizabeth A Greene; Rachel Sparks; Christopher S Carlson; John D Potter
Journal:  Hum Mutat       Date:  2002-11       Impact factor: 4.878

5.  Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue.

Authors:  J Stjernschantz; G Selén; B Sjöquist; B Resul
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1995

6.  Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1).

Authors:  Craig R Lee; Frank G Bottone; Joseph M Krahn; Leping Li; Harvey W Mohrenweiser; Molly E Cook; Robert M Petrovich; Douglas A Bell; Thomas E Eling; Darryl C Zeldin
Journal:  Pharmacogenet Genomics       Date:  2007-02       Impact factor: 2.089

7.  MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure.

Authors:  Padmanabhan P Pattabiraman; Paula E Pecen; Ponugoti Vasantha Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-05       Impact factor: 4.799

8.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

9.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

10.  Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.

Authors:  Jeffrey J W Verschuren; Helèn Boden; Judith A M Wessels; Bas L van der Hoeven; Stella Trompet; Bastiaan T Heijmans; Hein Putter; Henk-Jan Guchelaar; Martin J Schalij; J Wouter Jukema
Journal:  Int J Cardiol       Date:  2012-08-29       Impact factor: 4.164

View more
  4 in total

1.  Glaucoma Treatment Outcomes in Open Angle Glaucoma Patients of African Descent.

Authors:  Brent Siesky; Alon Harris; Aditya Belamkar; Ryan Zukerman; Avery Horn; Alice Verticchio Vercellin; Kristen A Mendoza; Paul A Sidoti; Francesco Oddone
Journal:  J Glaucoma       Date:  2022-03-29       Impact factor: 2.290

Review 2.  Pharmacogenomics of Prostaglandin and Leukotriene Receptors.

Authors:  José A Cornejo-García; James R Perkins; Raquel Jurado-Escobar; Elena García-Martín; José A Agúndez; Enrique Viguera; Natalia Pérez-Sánchez; Natalia Blanca-López
Journal:  Front Pharmacol       Date:  2016-09-21       Impact factor: 5.810

Review 3.  Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review.

Authors:  Yasutaka Takagi; Kazunori Santo; Masayo Hashimoto; Takeo Fukuchi
Journal:  Clin Ophthalmol       Date:  2018-09-21

4.  Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice.

Authors:  Laura M Dutca; Danielle Rudd; Victor Robles; Anat Galor; Mona K Garvin; Michael G Anderson
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.